4-(5-(4-氯苯基)-3-(三氟甲基)-1H-
| 中文名称 | 4-(5-(4-氯苯基)-3-(三氟甲基)-1H- |
|---|---|
| 中文同义词 | 4-(5-(4-氯苯基)-3-(三氟甲基)-1H-;4-(5-(4-氯苯基)-3-(三氟甲基)-1H-吡唑-1-基)苯磺酰胺 |
| 英文名称 | 4-[5-(4-CHLOROPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE |
| 英文同义词 | SC-236;4-[5-(4-CHLOROPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE;4-[5-(4-CHLOROPHENYL)-3-(TRIFLUOROMETHYL)PYRAZOL-1-YL]BENZENESULFONAMIDE;SC-58236;Benzenesulfonamide, 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-;SC 236 - SC 58236;SC-236,gastric,PPAR,cancer,ischemia,Liver,inhibit,allodynia,Inhibitor,fibrogenesis,neuroprotection,COX,Cyclooxygenase,Apoptosis,TNF-α,Peroxisome proliferator-activated receptors,fibrosis,SC236 |
| CAS号 | 170569-86-5 |
| 分子式 | C16H11ClF3N3O2S |
| 分子量 | 401.79 |
| EINECS号 | |
| 相关类别 | Amines;Apoptosis;Heterocycles;Inhibitors;Intermediates & Fine Chemicals;Pfizer compounds;Pharmaceuticals |
| Mol文件 | Mol File |
| 结构式 |  |
4-(5-(4-氯苯基)-3-(三氟甲基)-1H- 性质
| 熔点 | 146-148°C |
|---|---|
| 沸点 | 543.4±60.0 °C(Predicted) |
| 密度 | 1.54±0.1 g/cm3(Predicted) |
| 储存条件 | 2-8°C |
| 溶解度 | 二甲基亚砜：>20mg/mL |
| 形态 | 粉末 |
| 酸度系数(pKa) | 9.66±0.10(Predicted) |
| 颜色 | 白色至类白色 |
|
COX-2 10 nM (IC 50 ) |
COX-1 17.8 μM (IC 50 ) |
SC-236 (15 μM, 30 min) suppresses the side effects of NSAIDs and prevented inflammation in vECs subjected to ALSS.
SC-236 significantly induces PPARγ expression in HSCs and acted as a potent PPARγ agonist in a luciferase-reporter trans-activation assay.
SC-236 strongly inhibits, in a time- and concentration-dependent manner, macrophage
viability.
SC-236, either alone or in combination with 15d-PGJ2, induced a marked pro-apoptotic effect in HSCs in culture.
SC-236 mediates antitumor effect by modulation of AP-1-signaling pathway.
Western Blot Analysis
| Cell Line: | vECs. |
| Concentration: | 15 μM |
| Incubation Time: | 30 min. |
| Result: | Showd significant reduction in COX-2 level and increase in IκBα level, thus preventing ALSS-induced NFκB activation and inflammation in vECs. |
Western Blot Analysis
| Cell Line: | COS 7 cells. |
| Concentration: | 3 and 10 μM. |
| Incubation Time: | 18 h (combined with 15d-PGJ 2 ). |
| Result: | Acted in a concentration-dependent manner as a PPARγ agonist. |
SC-236 (6 mg/kg, gavage) exhibits anti-fibrotic properties in CCl4- treated animals.
| Animal Model: | Seventy-six male adult Wistar rats weighing 200-220 g (CCl 4 -treated). |
| Dosage: | 6 mg/kg. |
| Administration: | Orally, 3 times per week. |
| Result: |
A marked induction of COX-2 protein expression was detected by immunohistochemistry in the liver of CCl4-treated rats.
Significantly reduced the degree of liver fibrosis. Dramatically suppressed α-SMA expression in CCl4-treated rats. |
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024/04/30 | HY-W010983 | 4-(5-(4-氯苯基)-3-(三氟甲基)-1H- SC-236 | 170569-86-5 | 5mg | 800元 |
| 2024/04/30 | HY-W010983 | 4-(5-(4-氯苯基)-3-(三氟甲基)-1H- SC-236 | 170569-86-5 | 10mg | 1200元 |